Prospective randomized clinical trial to evaluate the optimal dose of131I for remnant ablation in patients with differentiated thyroid carcinoma

Abstract

Increasing the empirical 131 I initial dose to more than 50 mCi results in plateauing of the dose-response curve and thus, conventional high dose remnant ablation needs critical evaluation. Based on dosimetry results, one should aim to deliver about 30,000 cGy to the thyroid remnant, as higher doses do not appear to yield a higher ablation rate.